Abstract: The present invention provides polynucleotide molecules encoding portions of the S protein from feline infectious peritonitis virus (FIPV). The present invention further provides polynucleotide molecules encoding the entire S protein or portions thereof from feline enteric coronavirus (FECV). The polynucleotide molecules of the present invention are useful as diagnostic reagents.

Abstract: The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine.

Abstract: The present invention provides methods for locating critical portions or sites on the spike protein (S protein) of SARS-associated coronavirus (SARS-CoV) responsible for the viral infection that causes Severe Acute Respiratory Syndrome (SARS). The present invention also provides new synthetic peptides targeting such critical portions or sites of the S protein of SARS-CoV for preventing or treating of SARS-CoV infection in a subject. The present invention further provides methods of testing antiviral activity exerted by antiviral agents using real-time quantitative PCR.

Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.

Abstract: The invention relates generally to the field of virology, and relates to the identification and characterization of the targets involved in the evasion strategy of viruses and to the use thereof in methods to identify anti-viral compounds. More in particular to identify compounds which are modulators of myosin light chain kinase (MLCK), a target within said entry and immune-evasion strategy.

Abstract: The invention relates generally to the field of virology, and relates to the identification and characterization of the targets involved in the evasion strategy of viruses and to the use thereof in methods to identify anti-viral compounds. More in particular to identify compounds which are modulators of myosin light chain kinase (MLCK), a target within said entry and immune-evasion strategy.

Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.

Abstract: Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

Abstract: Provided are SARS-CoV detection PCR primers having nucleotide sequences as set forth in SEQ ID NOS: 1-46, a method for detecting SARS-CoV using the primers, and a SARS-CoV detection kit including the primers.

Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.

Abstract: The present invention is directed to an isolated polypeptide containing SEQ ID NO: 1 or an immunogenic fragment thereof. Also disclosed is an isolated nucleic acid encoding the polypeptide or containing a sequence at least 70% identical to SEQ ID NO: 3. Within the scope of this invention are related expression vectors, host cells, and antibodies. Also disclosed are methods of producing the polypeptide, diagnosing coronavirus infection, and identifying a test compound for treating coronavirus infection.

Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.

Abstract: Methods for determining the presence of SARS-CoV in a test sample that include targeting the SARS-CoV 5? leader sequence or the SARS-CoV 3? terminal sequence.

Abstract: The present invention relates to the use of novel nucleotide sequences for the spike peptide, pol region peptide and M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.

Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the nucleocapsid gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARSCoV infection.

Abstract: Primers and probes derived from SARS-CoV nucleic acid that facilitate detection and/or quantification of the replicase gene are disclosed. The disclosed sequences may be used in a variety of amplification and non-amplification formats for detection of SARS-CoV infection.

Abstract: Provided are nucleic acid primers and probes for use in diagnostic assays to screen for respiratory infections, such as respiratory syncytial virus (“RSV”) and human metapneumovirus (hMPV). The primers and probes may be used to screen for RSV or hMPV in a singleplex assay or they may be used in a multiplex assay to simultaneously screen for RSV and hMPV, or RSV and/or hMPV and any of the following viruses: influenza A, and influenza B, parainfluenza viruses, adenovirus, coronavirus, and rhinoviruses.

Abstract: The present invention relates generally to the field of nucleic acid detection and more specifically to the detection of human respiratory viruses in a patient sample. In some aspects, the invention relates to the detection of multiple respiratory viral groups, including rhinovirus, respiratory syncytial virus, parainfluenza virus, influenza virus, metapneumovirus, adenovirus, coronavirus, and enterovirus.

Abstract: The present invention relates to the use of novel nucleotide sequences for the M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.